On a non-GAAP basis, gross margin increased from 80.6% to 81.1% in the quarter primarily driven by lower royalties. Gross margin increased from 76.3% to 80.3% in the quarter primarily due to lower unwinding of inventory purchase price accounting adjustments.
When adjusted for foreign exchange impact, international revenues increased 6%. International revenues increased 8% to $4.3 billion in the quarter, driven by higher demand for Eliquis, Revlimid and Opdivo. revenues increased 12% to $7.3 billion in the quarter, driven by higher demand for Revlimid, Eliquis and our new product portfolio. $ amounts in millions, except per share amountsĪll comparisons are made versus the same period in 2020 unless otherwise stated.īristol Myers Squibb posted third quarter revenues of $11.6 billion, an increase of 10%, driven by Revlimid, Eliquis, Opdivo and our new product portfolio. Our deep and diverse product pipeline, commercial execution and financial flexibility provide a strong foundation that is enabling the company to bring new medicines that benefit patients with serious unmet needs, drive in-line product performance and deliver sustained growth.” “Our teams advanced the product portfolio and achieved significant regulatory and clinical milestones, including for the fixed-dose combination of relatlimab and nivolumab. “Our strong results reflect increased adoption of our new product portfolio and continued demand growth across all four core therapeutic areas,” said Giovanni Caforio, M.D., board chair and chief executive officer, Bristol Myers Squibb. NEW YORK-(BUSINESS WIRE)- Bristol Myers Squibb (NYSE:BMY) today reports results for the third quarter of 2021, which reflect solid sales, strong commercial execution and continued progress of the company’s pipeline.
0 kommentar(er)
